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fatty acids. The major precursor Arachidonic acid (all-cis-5,8,11,14-
eicosatetraenoic acid) is metabolized to prostaglandins (PG) and prosta-
cyclin (PGI) by the cyclooxygenase (COX) pathway, while leukotri-
enes are formed via the lipoxygenase (LOX) pathway. These down 
stream lipid metabolites are thought to be involved in carcinogenesis, 
and ample preclinical ﬁndings support modulations of arachidonic acid 
pathways for inhibition of carcinogenesis. There are two main isoforms 
of COX: COX-1 and COX-2. COX-1 exists in most cells and is consti-
tutively active. In contrast, COX-2 is an inducible enzyme that is up-
regulated by carcinogens, inﬂammatory and mitogenic stimuli. COX-2 
is primarily responsible for the overproduction of PG in inﬂamed, as 
well as neoplastic tissues. Overproduction of PGE2 is associated with 
a variety of carcinogenic mechanism, including abnormal expression 
of epithelial growth factors, epithelial and microvascular proliferation, 
resistance to apoptosis and inhibition of antitumor immunity.
COX-2 expression has been demonstrated in premalignant bronchial 
tissue and lung cancer. Patients with higher levels of COX-2 expres-
sion in their tumors have a poorer prognosis. In murine models, COX-2 
inhibition impedes lung tumorigenesis, decreases the rate of growth of 
lung cancer and number and size of metastasis. Expression of COX-2 
has been shown to enhance tumorigenesis by regulation of angiogen-
esis via CXC chemokines and EGFR, invasion via CD44 and matrix 
metalloproteinases, apoptosis via survivin and insulin like growth 
factor, and anti-tumor immunity via IL-10 and IL-12. Several clini-
cal trials addressing the use of Celecoxib for lung cancer prevention 
are underway. Results of a pilot, phase IIa trial in high-risk smokers 
performed at UCLA suggest that Celecoxib may modulate SEBM with 
reduction of PGE2 production, restoration of anti-tumor immunity and 
reduction of proliferation indices (Ki-67 labeling index). A follow-up 
larger phase IIb trial focusing on heavy former smokers is evaluating 
the effect of Celecoxib on cellular and molecular events associated with 
lung carcinogenesis. Another phase IIb trial of Celecoxib in current and 
former smokers is being conducted at MD Anderson Cancer Center. 
Moreover, A multicenter study with the lead center at Mayo Clinic us-
ing Sulindac, a nonspeciﬁc COX inhibitor, is also recruiting patients. 
5-lipooxygenase (LOX) is an enzyme involved in the conversion of 
arachidonic acid to leukotrienes. Leukotrienes have been implicated to 
play a prominent inductive role in lung carcinogenesis. This is based on 
data demonstrating that 5-LOX is expressed in lung cancers and 5-LOX 
inhibitors reduced the multiplicity and incidence of lung tumors in 
mice. A Phase II Clinical trial of the 5-LOX inhibitor Zileuton has been 
conducted at the Karmanos Cancer Institute addressing the effect of 
Zileuton on bronchial dysplasia and multiple SEBM in at-risk smokers 
or patients with curatively treated aerodigestive cancers.
Another arachidonic acid metabolite of interest is prostacyclin (PGI). 
It has been demonstrated that up-regulation of PGI decreased tumori-
genicity in mice exposed to carcinogens. A multicenter study with the 
lead center at the University of Colorado is currently enrolling smokers 
and ex-smokers with sputum atypia in a phase II randomized clinical 
trial to evaluate the effectiveness of Iloprost, a synthetic analog of PGI. 
Endpoints include comparisons of phenotypic modulation of bronchial 
epithelium between the two groups, as well as evaluation of multiple 
SEBM. 
Numerous clinical studies evaluating promising agents in lung cancer 
chemoprevention are underway. Important goals for future chemopre-
vention trials include devising strategies to minimize toxicity, identify 
and validate appropriate SEBM. To this end, integration of new diag-
nostic technologies such as ﬂuorescence bronchscopy and spiral CT, 
molecular proﬁling of risks, using high-throughput technology such 
as genomics microarray and proteomics, for therapeutic stratiﬁcation 
and monitoring, will collectively facilitate the development of effective 
paradigms for prevention, early detection and treatment of lung cancer. 
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Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-
TKIs) given concurrently with chemotherapy do not improve patient 
outcomes compared to chemotherapy alone in advanced non-small cell 
lung cancer (NSCLC). One potential explanation for this lack of beneﬁt 
is a negative interaction or antagonism between chemotherapy and 
EGFR TKIs when delivered concomitantly. Support for this line of rea-
soning is provided by preclinical data demonstrating that EGFR TKIs 
induce primarily a cytostatic effect resulting from a G1 cell cycle arrest 
in cell lines with wild type (WT) EGFR, reducing cell cycle phase-de-
pendent activity of chemotherapy, whereas they induce apoptotic cell 
death in tumors with EGFR activating mutations. Thus, sequence-spe-
ciﬁc interactions of EGFR TKI-chemotherapy combinations may nega-
tively inﬂuence the efﬁcacy of these regimens in patients with NSCLC. 
Preclinical and clinical rationale for studies examining the concept of 
pharmacodynamic separation as a means for overcoming hypothesized 
antagonism of EGFR TKIs and chemotherapy as well as recent clinical 
trial results will be discussed.
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In the last years the identiﬁcation of a number of molecular targets 
essential and speciﬁc for tumor growth, cell proliferation and metas-
tasis development has produced a new class of anticancer drugs, the 
molecular targeted therapies.
Molecular biology has clearly identiﬁed many different tumoral meta-
bolic pathways which are active and crucial to neoplastic phenotype 
across different histologic solid tumors. Among these, the HER family 
receptors and neoangiogenesis have been particularly studied and a 
number of new drugs that inhibit speciﬁc growth factors such as epi-
dermal growth factors (EGF) and vascular endothelial growth factors 
(VEGF) have been developed through phase I-II-III trials as single 
agents or in combination with chemotherapy and some have been 
already registered for the treatment of advanced Non Small Cell Lung 
Cancer (NSCLC).
Among many factors related in promoting angiogenesis, Vascular 
Endothelial Growth Factor (VEGF) has a recognized critical rate-limit-
ing role because of its ability to regulate key steps in the angiogenesis 
